| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 09/20/2001 | CA2400106A1 Antibodies to human cd154 |
| 09/20/2001 | CA2373110A1 Production of chimeric capsid vectors |
| 09/19/2001 | EP1134215A1 2-oxo-imidazolidine-4-carboxylic acid hydroxamine compounds that inhibit matrix metalloproteinases |
| 09/19/2001 | EP1133992A1 Novel pharmacological activities of curcuma longa extracts |
| 09/19/2001 | EP1133563A2 Methods and molecules relating to cd39-like polypeptides |
| 09/19/2001 | EP1133555A2 Pharmaceutical factor vii preparation |
| 09/19/2001 | EP1133489A1 Isonipecotamides for the treatment of integrin-mediated disorders |
| 09/19/2001 | EP1133488A1 Propanoic acid derivatives as integrin inhibitors |
| 09/19/2001 | EP1133486A2 Nonsteroidal antiinflammatories |
| 09/19/2001 | EP1133475A1 Substituted benzo de]isoquinoline-1,3-diones |
| 09/19/2001 | EP1133471A1 Hydrazine derivatives |
| 09/19/2001 | EP1133314A1 Method of treating sickle cell disease and thalassemia |
| 09/19/2001 | EP1133308A1 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases |
| 09/19/2001 | EP1133291A1 Methods of treating thrombocytopenia |
| 09/19/2001 | EP1133287A2 Use of 17-ketosteroids for the treatment of hepatitis c virus and other togaviruses |
| 09/19/2001 | EP1133278A2 Delivery of liposomal-encapsulated antioxidants and applications thereof |
| 09/19/2001 | EP0923529B1 Substitute 4-arylbutyric acid derivatives as matrix metalloprotease inhibitors |
| 09/19/2001 | EP0800516B1 FIBRINOGEN RECEPTOR ANTAGONISTS HAVING SUBSTITUTED (b)-AMINO ACID RESIDUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME |
| 09/19/2001 | EP0692984B1 Systemic effects of nitric oxide inhalation |
| 09/19/2001 | EP0594667B1 Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
| 09/19/2001 | CN1313855A Inhibitors of alpha4Betal mediated cell adhesion alpha Beta |
| 09/19/2001 | CN1313846A C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cystenine proteases |
| 09/19/2001 | CN1313343A N-terminal modified protein compositions and methods therefor |
| 09/19/2001 | CN1313280A Benzheterocyclic derivatives |
| 09/19/2001 | CN1071336C Compositions by using unbound MPL receptor for stimulating platelet production |
| 09/18/2001 | US6291522 Cyclopentane heptan(ENE)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents |
| 09/18/2001 | US6291516 Contacting the cell with a composition including at least one cyclic amp agonist. |
| 09/18/2001 | US6291469 Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation |
| 09/18/2001 | US6291458 Morpholinobenzamide salts |
| 09/18/2001 | US6291440 Iron-dextran compound for use as a component in a therapeutical composition for prophylaxis or treatment of iron-deficiency |
| 09/18/2001 | US6291425 Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| 09/18/2001 | CA2735316A1 Thrombin preparations and process for their production |
| 09/18/2001 | CA2236814C Quinoline and quinazoline compounds useful in therapy |
| 09/18/2001 | CA2194485C Endothelial lining effects and treatment of vasospastic disorders |
| 09/18/2001 | CA2036197C Modified hil-6 |
| 09/15/2001 | WO2001066747A2 Proteins named fctrx and nucleic acids encoding same |
| 09/15/2001 | CA2401552A1 Proteins named fctrx and nucleic acids encoding same |
| 09/13/2001 | WO2001066746A2 G-protein coupled receptor related polypeptides |
| 09/13/2001 | WO2001066742A2 G-protein coupled receptors |
| 09/13/2001 | WO2001066594A2 Human protein kinases and protein kinase-like enzymes |
| 09/13/2001 | WO2001066557A1 Adam polynucleotides, polypeptides, and antibodies |
| 09/13/2001 | WO2001066548A1 New aza-indolyl derivatives |
| 09/13/2001 | WO2001066544A2 Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers |
| 09/13/2001 | WO2001066521A1 Azacyclic compounds for use in the treatment of serotonin related diseases |
| 09/13/2001 | WO2001066159A1 Novel natural polymer-based material with improved properties for use in human and veterinary medicine and the method of manufacturing such |
| 09/13/2001 | WO2001066141A1 Remedies and preventives for antiphospholipid antibody syndrome |
| 09/13/2001 | WO2001066140A1 Use of tgf-beta antagonists to treat or to prevent loss of renal function |
| 09/13/2001 | WO2001066139A1 Use of a compound that selectively binds to cd123 to impair hematologic cancer progenitor cell |
| 09/13/2001 | WO2001066085A2 Micellar pharmaceutical compositions for buccal and pulmonary application |
| 09/13/2001 | WO2001066081A2 Pharmaceutical preparations containing saccharose fatty acid esters for controlling the release of active ingredients |
| 09/13/2001 | WO2001029178A3 Epo primary response gene 1, eprg1 |
| 09/13/2001 | WO2001028492A3 Polyanhydrides with biologically active degradation products |
| 09/13/2001 | WO2001009138A3 Chemokine receptor antagonists and methods of use therefor |
| 09/13/2001 | US20010021775 Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor Xa |
| 09/13/2001 | US20010021713 Thromboresistant materials incorporating pyrazinone protease inhibitors |
| 09/13/2001 | US20010021516 An isolated nucleic acid molecule comprising a polynucleotide having nucleotide sequence atleast 95% identical to a sequence selected from a nucleotide sequence encoding a TRID polypeptide having specific amino acid sequence |
| 09/13/2001 | US20010021400 Tanacetum parthenium extract and method of obtaining same |
| 09/13/2001 | CA2402179A1 Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers |
| 09/13/2001 | CA2402081A1 A compound that selectively binds to cd123 and use thereof to kill hematologic cancer progenitor cells |
| 09/13/2001 | CA2401549A1 G-protein coupled receptor related polypeptides |
| 09/13/2001 | CA2401541A1 Human protein kinases and protein kinase-like enzymes |
| 09/13/2001 | CA2401454A1 G-protein coupled receptors |
| 09/13/2001 | CA2400628A1 Use of tgf-beta antagonists to treat or to prevent loss of renal function |
| 09/13/2001 | CA2400401A1 Novel natural polymer-based material with improved properties for use in human and veterinary medicine and the method of manufacturing such |
| 09/13/2001 | CA2399913A1 Adam polynucleotides, polypeptides, and antibodies |
| 09/13/2001 | CA2399111A1 New aza-indolyl derivatives |
| 09/12/2001 | EP1132389A1 New aza-indolyl derivatives for the treatment of obesity |
| 09/12/2001 | EP1132382A1 3-Oxy-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadazine-1,1-dioxide derivatives having diuretic and/or natriuretic activity |
| 09/12/2001 | EP1132092A1 Coupling factor 6 inhibitor and potentiator and use thereof |
| 09/12/2001 | EP1131467A2 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
| 09/12/2001 | EP1131445A1 Human phospholipases |
| 09/12/2001 | EP1131428A2 Immunoglobulin superfamily proteins |
| 09/12/2001 | EP1131327A1 Prostaglandin conjugates for treating or preventing bone disease |
| 09/12/2001 | EP1131320A1 Isoxazoline fibrinogen receptor antagonists |
| 09/12/2001 | EP1131315A1 Polyhydroxylated heterocyclic derivatives as anti-coagulants |
| 09/12/2001 | EP1131301A1 2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof |
| 09/12/2001 | EP1131292A2 Acyclic and cyclic guanidine- and acetamidine derivatives, their preparation and their use as pesticides, esp. as parasiticides |
| 09/12/2001 | EP1131106A1 Compositions and methods for producing vascular occlusion |
| 09/12/2001 | EP1131091A1 Method of treating viral hemorrhagic fever |
| 09/12/2001 | EP1131085A2 Use of parvovirus capsid particles in the inhibition of cell proliferation and migration |
| 09/12/2001 | EP1131065A2 Utilisation of dialkylfumarates |
| 09/12/2001 | EP0929572A4 Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides |
| 09/12/2001 | EP0833848B1 Factor ix binding peptides, derived from factor viii and their use as inhibitors of blood coagulation |
| 09/12/2001 | EP0789585B1 A storage stable water solution for infusion containing a thrombin inhibitor |
| 09/12/2001 | EP0749424B1 Naphthalene derivatives as prostaglandin i2 agonists |
| 09/12/2001 | CN1312799A Bispiperidines as antithrombotic agents |
| 09/12/2001 | CN1312724A TNF-drvived peptides of use in treating oedema |
| 09/12/2001 | CN1312719A Pharmaceutical Composition |
| 09/12/2001 | CN1312294A Human blood and blood vessel cytopoiesis hormone and its preparation |
| 09/12/2001 | CN1070866C Superagonists and antagonists and superantagonists of H IL-6, and 3-D modelling method for their selection |
| 09/12/2001 | CN1070710C Composition extracted from collagen and Japanese beanty berry and preparation thereof |
| 09/11/2001 | US6288231 Peptide-containing α-ketoamide cysteine and serine protease inhibitors |
| 09/11/2001 | US6288105 Antithrombotic agents |
| 09/11/2001 | US6288077 2,3-methano-amino acid compounds |
| 09/11/2001 | US6288056 Intermittent claudication therapeutic drugs comprising pyrroloazepines |
| 09/11/2001 | US6288029 Template assembled synthetic peptide effective to treat respiratory system disorders |
| 09/11/2001 | US6288027 Preserving a hemoglobin blood substitute with a transparent overwrap |
| 09/11/2001 | US6287794 Peptide having antithrombotic effect through reversible inhibition of blood coagulation factor; antiinflammatory agents; treatment of cardiovascular disorders |
| 09/11/2001 | US6287786 Nucleic acid molecules encoding a new mammalian protein and to the use of these molecules in the characterization, diagnosis, and treatment of conditions such as disorders associated with cell proliferation, lipid metabolism and transport. |
| 09/11/2001 | US6287599 Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |